Literature DB >> 32901

A pharmacokinetic study of doxapram in patients and volunteers.

R H Robson, L F Prescott.   

Abstract

1. Following intravenous bolus injections or brief infusions in healthy volunteers, plasma concentrations of doxapram declined in a multi-exponential fashion. The mean half-life from 4-12 h was 3.4 h (range 2.4-4.1h), the mean apparent volume of distribution was 1.5 1 kg-1 and the whole body clearance was 370 ml min-1. 2. Enteric-coated capsules of doxapram base were absorbed rapidly after an initial delay, and the systemic availability was about 60%. 3. Doxapram is extensively metabolized and less than 5% of an i.v. dose was excreted unchanged in the urine in 24 h. A metabolite (AHR 5955) was present in plasma in amounts comparable to the parent compound and had a similar half-life. 4. The disposition of doxapram appears to be similar in healthy volunteers and patients with respiratory failure. 5. The previously held belief that plasma concentrations fall rapidly when an infusion is stopped is only true following short duration infusions. The pharmacokinetic properties of doxapram are such that steady-state plasma concentrations will not be achieved for many hours with the recommended constant rate infusion régime.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 32901      PMCID: PMC1429614          DOI: 10.1111/j.1365-2125.1979.tb00901.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  A controlled trail of doxapram in acute respiratory failure.

Authors:  J F Riordan; R W Sillett; M W McNicol
Journal:  Br J Dis Chest       Date:  1975-01

2.  EXCRETION, DISTRIBUTION, AND METABOLISM OF DOXAPRAM HYDROCHLORIDE.

Authors:  R B BRUCE; J E PITTS; F PINCHBECK; J NEWMAN
Journal:  J Med Chem       Date:  1965-03       Impact factor: 7.446

3.  [Methods for biopharmaceutical evaluation of enteric gelatin capsules: use of Enterocaps gelatin capsules].

Authors:  J M Aiache; S Aiache; A Jeanneret; F Cornat
Journal:  Boll Chim Farm       Date:  1975-11

4.  Rapid gas--liquid chromatographic estimation of doxapram in plasma.

Authors:  R H Robson; L F Prescott
Journal:  J Chromatogr       Date:  1977-09-01

5.  The use of doxapram in the newborn.

Authors:  P K Gupta; J Moore
Journal:  J Obstet Gynaecol Br Commonw       Date:  1973-11

6.  Role of doxapram in reducing pulmonary complications after major surgery.

Authors:  T H Gawley; J W Dundee; P K Gupta; C J Jones
Journal:  Br Med J       Date:  1976-01-17

7.  Proceedings: Absorption, distribution and excretion of doxapram hydrochloride in the rat.

Authors:  C J Jones; D K Luscombe; P J Nicholls
Journal:  J Pharm Pharmacol       Date:  1973-12       Impact factor: 3.765

  7 in total
  10 in total

1.  Serum doxapram and respiratory neuromuscular drive in normal man.

Authors:  S Okubo; K Konno; T Ishizaki; T Suganuma; T Takubo; T Takizawa; M Tanaka
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  A new look at the respiratory stimulant doxapram.

Authors:  C Spencer Yost
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

3.  A simple method for the administration of doxapram.

Authors:  M Mattila; I Larma
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

4.  Normal pharmacokinetics of doxapramin in a patient with renal failure and hypothyroidism.

Authors:  J R Baker; C C Peck; B D Raybuck; E L Owens; B G Schuster
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

5.  Hepatic necrosis with doxapram hydrochloride.

Authors:  G J Fancourt; R J Ashton; I C Talbot; J M Wales
Journal:  Postgrad Med J       Date:  1985-09       Impact factor: 2.401

6.  Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial.

Authors:  E Greze; M Benard; I Hamon; C Casper; F E Haddad; M-J Boutroy; J-M Hascoët
Journal:  Paediatr Drugs       Date:  2016-12       Impact factor: 3.022

7.  The disposition of intravenous doxapram in man.

Authors:  J A Clements; R H Robson; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

8.  Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea.

Authors:  Yuki Ogawa; Mitsuru Irikura; Yuka Kobaru; Mayu Tomiyasu; Yoshie Kochiyama; Mamiko Uriu; Yoichi Ishitsuka; Yuki Kondo; Eiji Yukawa; Noboru Kamada; Hitoshi Ohno; Toshio Yamazaki; Tetsumi Irie
Journal:  Eur J Pediatr       Date:  2014-09-25       Impact factor: 3.183

9.  Simultaneous Quantification and Pharmacokinetic Characterization of Doxapram and 2-Ketodoxapram in Porcine Plasma and Brain Tissue.

Authors:  Manuel Kraft; Kathrin I Foerster; Felix Wiedmann; Max Sauter; Amelie Paasche; Pablo L Blochberger; Baran Yesilgöz; Yannick L'hoste; Norbert Frey; Walter E Haefeli; Jürgen Burhenne; Constanze Schmidt
Journal:  Pharmaceutics       Date:  2022-03-31       Impact factor: 6.321

10.  The bioavailability and maturing clearance of doxapram in preterm infants.

Authors:  Robert B Flint; Sinno H P Simons; Peter Andriessen; Kian D Liem; Pieter L J Degraeuwe; Irwin K M Reiss; Rob Ter Heine; Aline G J Engbers; Birgit C P Koch; Ronald de Groot; David M Burger; Catherijne A J Knibbe; Swantje Völler
Journal:  Pediatr Res       Date:  2020-07-22       Impact factor: 3.756

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.